Current Diabetes Reports

, Volume 10, Issue 2, pp 116–123 | Cite as

Update on the Safety of Thiazolidinediones



Diabetic patients are at increased risk for developing cardiovascular disease, and they constitute a large proportion of the global cardiovascular disease burden. Although multiple drugs exist for treating the hyperglycemia associated with diabetes, few have been shown to reduce cardiovascular risk. Great hope surrounded the arrival of the thiazolidinediones—drugs that favorably affect insulin sensitivity, inflammation, and some aspects of lipid profiles in diabetic patients. However, the cardiovascular effects of these agents are varied, and studies have suggested that they may be associated with increases in ischemic heart disease and heart failure, as well as with an increased risk for bone fracture. The following article provides a summary of important studies that have been published regarding the safety profiles of these agents. Findings from two recently published trials, RECORD and BARI 2D, are emphasized in this paper.


Thiazolidinediones Cardiovascular disease Rosiglitazone Pioglitazone 


Papers of particular interest, published recently, have been highlighted as follows: • Of importance •• Of major importance

  1. 1.
    King H, Aubert RE, Herman WH: Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998, 21:1414–1431.CrossRefPubMedGoogle Scholar
  2. 2.
    Preis SR, Pencina MJ, Hwang S, et al.: Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation 2009, 120:212–220.CrossRefPubMedGoogle Scholar
  3. 3.
    Fox CS, Coady S, Sorlie PD, et al.: Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation 2007, 115:1544–1550.CrossRefPubMedGoogle Scholar
  4. 4.
    Huang ES, Meigs JB, Singer DE: The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 2001, 111:633–642.CrossRefPubMedGoogle Scholar
  5. 5.
    Kelly TN, Bazzano LA, Fonseca VA, et al.: Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009, 151:394–403.PubMedGoogle Scholar
  6. 6.
    Effects of intensive glucose lowering in type 2 diabetes. The Action to Control Cardiovascular Risk in Diabetes Study Group [no authors listed]. N Engl J Med 2008, 358:2545–2559.Google Scholar
  7. 7.
    Duckworth W, Abraira C, Moritz T, et al.: Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129–139.CrossRefPubMedGoogle Scholar
  8. 8.
    Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The ADVANCE Collaborative Group [no authors listed]. N Engl J Med 2008, 358:2560–2572.Google Scholar
  9. 9.
    Holman RR, Paul SK, Bethel MA, et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577–1589.CrossRefPubMedGoogle Scholar
  10. 10.
    Gleissner CA, Galkina E, Nadler JL, Ley K: Mechanisms by which diabetes increases cardiovascular disease. Drug Discov Today Dis Mech 2007, 4:131–140.CrossRefPubMedGoogle Scholar
  11. 11.
    Lebovitz HE: Rationale for and role of thiazolidinediones in type 2 diabetes mellitus. Am J Cardiol 2002, 90:34G–41G.CrossRefPubMedGoogle Scholar
  12. 12.
    Agarwal R: Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. Am J Physiol Renal Physiol 2006, 290:F600–F605.CrossRefPubMedGoogle Scholar
  13. 13.
    Katavetin P, Eiam-Ong S, Suwanwalaikorn S: Pioglitazone reduces urinary protein and urinary transforming growth factor-beta excretion in patients with type 2 diabetes and overt nephropathy. J Med Assoc Thai 2006, 89:170–177.PubMedGoogle Scholar
  14. 14.
    Tolman KG, Chandramouli J: Hepatotoxicity of the thiazolidinediones. Clin Liver Dis 2003, 7:369–379, vi.CrossRefPubMedGoogle Scholar
  15. 15.
    Patel RR: Thiazolidinediones and congestive heart failure: a judicious balance of risks and benefits. Cardiol Rev 2009, 17:132–135.CrossRefPubMedGoogle Scholar
  16. 16.
    Dormuth CR, Carney G, Carleton B, et al.: Thiazolidinediones and fractures in men and women. Arch Intern Med 2009, 169:1395–1402.CrossRefPubMedGoogle Scholar
  17. 17.
    •• Nissen SE, Wolski K: Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007, 356:2457–2471. This meta-analysis created a great deal of debate and concern regarding the cardiovascular risks associated with the TZDs when it was released.CrossRefPubMedGoogle Scholar
  18. 18.
    Singh S, Loke YK, Furberg CD: Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007, 298:1189–1195.CrossRefPubMedGoogle Scholar
  19. 19.
    Home PD, Pocock SJ, Beck-Nielsen H, et al.: Rosiglitazone evaluated for cardiovascular outcomes—an interim analysis. N Engl J Med 2007, 357:28–38.CrossRefPubMedGoogle Scholar
  20. 20.
    Mannucci E, Monami M: Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing? Curr Diab Rep 2009, 9:342–347.CrossRefPubMedGoogle Scholar
  21. 21.
    Mannucci E, Monami M, Di Bari M, et al.: Cardiac safety profile of rosiglitazone: a comprehensive meta-analysis of randomized clinical trials. Int J Cardiol 2009 Mar 26 [Epub ahead of print].Google Scholar
  22. 22.
    Dormandy JA, Charbonnel B, Eckland DJ, et al.: Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279–1289.CrossRefPubMedGoogle Scholar
  23. 23.
    Erdmann E, Dormandy JA, Charbonnel B, et al.: The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007, 49:1772–1780.CrossRefPubMedGoogle Scholar
  24. 24.
    Lincoff AM, Wolski K, Nicholls SJ, Nissen SE: Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180–1188.CrossRefPubMedGoogle Scholar
  25. 25.
    Mannucci E, Monami M, Lamanna C, et al.: Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes Metab 2008, 10:1221–1238.CrossRefPubMedGoogle Scholar
  26. 26.
    •• Home PD, Pocock SJ, Beck-Nielsen H, et al.: Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125–2135. This study is one of the first RCTs with a goal of determining the cardiovascular risk associated with a TZD.CrossRefPubMedGoogle Scholar
  27. 27.
    McCall AL: When is evidence of lack of harm enough? Has the rosiglitazone controversy ended? Curr Diab Rep 2009, 9:325–328.CrossRefPubMedGoogle Scholar
  28. 28.
    Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators [no authors listed]. N Engl J Med 1996, 335:217–225.Google Scholar
  29. 29.
    •• Frye RL, August P, Brooks MM, et al.: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009, 360:2503–2515. This study is a more recent RCT reviewing the effects of IS agents on cardiovascular risk.CrossRefPubMedGoogle Scholar
  30. 30.
    Chaitman BR, Hardison RM, Adler D, et al.: The Bypass Angioplasty Revascularization Investigation 2 Diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009, 120:2529–2540.CrossRefPubMedGoogle Scholar
  31. 31.
    Guan Y, Hao C, Cha DR, et al.: Thiazolidinediones expand body fluid volume through PPARgamma stimulation of ENaC-mediated renal salt absorption. Nat Med 2005, 11:861–866.CrossRefPubMedGoogle Scholar
  32. 32.
    Karalliedde J, Buckingham R, Starkie M, et al.: Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 2006, 17:3482–3490.CrossRefPubMedGoogle Scholar
  33. 33.
    Ali AA, Weinstein RS, Stewart SA, et al.: Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005, 146:1226–1235.CrossRefPubMedGoogle Scholar
  34. 34.
    Lecka-Czernik B, Ackert-Bicknell C, Adamo ML, et al.: Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 2007, 148:903–911.CrossRefPubMedGoogle Scholar
  35. 35.
    Kahn SE, Haffner SM, Heise MA, et al.: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427–2443.CrossRefPubMedGoogle Scholar
  36. 36.
    Meier C, Kraenzlin ME, Bodmer M, et al.: Use of thiazolidinediones and fracture risk. Arch Intern Med 2008, 168:820–825.CrossRefPubMedGoogle Scholar
  37. 37.
    Schwartz AV, Sellmeyer DE, Vittinghoff E, et al.: Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab 2006, 91:3349–3354.CrossRefPubMedGoogle Scholar
  38. 38.
    Aronoff S, Rosenblatt S, Braithwaite S, et al.: Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000, 23:1605–1611.CrossRefPubMedGoogle Scholar
  39. 39.
    Lebovitz HE, Dole JF, Patwardhan R, et al.: Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001, 86:280–288.CrossRefPubMedGoogle Scholar
  40. 40.
    Goldberg RB, Kendall DM, Deeg MA, et al.: A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005, 28:1547–1554.CrossRefPubMedGoogle Scholar
  41. 41.
    Starner CI, Schafer JA, Heaton AH, Gleason PP: Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events. J Manag Care Pharm 2008, 14:523–531.PubMedGoogle Scholar
  42. 42.
    Fisman EZ, Tenenbaum A: A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. Cardiovascular Diabetology 2009, 8:38.CrossRefPubMedGoogle Scholar
  43. 43.
    Duncker DJ, Van Zon NS, Altman JD, et al.: Role of K+ATP channels in coronary vasodilation during exercise. Circulation 1993, 88:1245–1253.PubMedGoogle Scholar
  44. 44.
    Garratt KN, Brady PA, Hassinger NL, et al.: Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999, 33:119–124.CrossRefPubMedGoogle Scholar
  45. 45.
    • Tzoulaki I, Molokhia M, Curcin V, et al.: Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 2009, 339b:4731. This retrospective study reviews the risk of CVD associated with various oral antidiabetic drugs.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of MedicineStrelitz Diabetes Center for Endocrine and Metabolic DisordersNorfolkUSA
  2. 2.Department of MedicineUniversity of Virginia Health SystemCharlottesvilleUSA

Personalised recommendations